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Abstract 
 
STRUCTURAL ELEMENTS OF LIPIDIC INHIBITORS OF PHOSPHOLIPASE A2 
 
James Foley 
B.A., Appalachian State University 
M.S., Appalachian State University 
 
 
Chairperson: Dr. Mark Venable 
 
 
 Phospholipases A2 (PLA2) are a family of enzymes that release fatty acids 
from phospholipids and play varied and important roles in the biology of all 
organisms. Secreted phospholipases A2 (sPLA2) are the largest subfamily of PLA2. 
sPLA2 expression levels have been positively correlated to the severity of multiple 
inflammatory diseases. Many sPLA2 inhibitors have been developed and tested, 
however, none have shown to be clinically effective and specific against individual 
enzymes within this family. In this study we discovered an inhibition phenomenon in 
a widely used sPLA2 enzymatic assay. The enzymatic rate of reaction of sPLA2 group 
IIA from Crotalus adamanteus was significantly reduced when negatively charged 
lipids were added at very low mole fractions. This inhibition phenomenon did not 
occur if the lipid added was either positively charged or polar but neutral. These 
results suggest that the standard assay should be re-optimized to prevent this 
nonspecific inhibition and that the literature may need to be reevaluated.  
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Introduction 
 Phospholipases A2 (PLA2s) are a superfamily of enzymes responsible for the 
hydrolysis of the fatty acid at the sn-2 glycerol position of membrane associated 
phospholipids. This hydrolysis results in a lysophospholipid and a free fatty acid; both of 
which can be used in various biological processes such as the formation of inflammatory 
eicosanoids (1, 2). Groups of PLA2s are denoted by roman numerals (PLA2GI, II, III…). 
Each group is separated according to unique features such as catalytic residue makeup, Ca2+ 
dependence, structure, and function. Each group contains various isoforms denoted by capital 
letters (PLA2GIA, B, C…). Each group can be vastly different from one another, but each 
isoform within the group is structurally/functionally similar. Researchers also prefix each 
PLA2 name with a lowercase letter that signifies a specific characteristic. The four 
characteristic group prefixes are secreted (s-), cytosolic (c-), Ca2+ independent (i-), and 
lipoprotein-associated (Lp-PLA2).  
 Secreted PLA2s (sPLA2s) are the largest family of phospholipases A2. They are small 
secreted proteins 14-18 kDa in size, contain a highly conserved Ca2+ binding domain, have a 
histidine (His) and aspartate (Asp) dyad in the active site, and have six conserved disulfide 
bonds. Due to the Ca2+-binding domain these enzymes are activated at millimolar 
concentrations of Ca2+ and thus are only catalytically active in the extracellular space after 
secretion. They are also very stable due to their small size and number of disulfide bonds, 
making them relatively easy to handle in vitro. Some organisms including humans express 
more than one group/isoform of sPLA2s in their tissues; this allows different tissues to have 
their own sPLA2 expression pattern and allow them to carry out specific functions with little 
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interference. The following sPLA2s are normally expressed in the human body: sPLA2GIB, 
IIA, IIF, III, V, and X. 
 Over the past few decades researchers have come to understand the structure, 
function, and expression patterns of sPLA2s. One of the most well-known and studied human 
sPLA2s is sPLA2GIIA. sPLA2GIIA was originally characterized as a “bactericidal sPLA2” 
due to its high affinity for phosphatidylethanolamine (PE) which makes up a lot of gram-
positive bacterial membranes (1). This is also supported by the fact that sPLA2GIIA is highly 
expressed in intestinal Paneth cells and tear glands which are commonly exposed to high 
levels of bacteria (2). Recently, this enzyme has been associated with inflammation due to its 
ability to release arachidonic acid (AA) from phosphatidylcholine (PC) (Figure 1), the  
 
Figure 1. Production of Arachidonic Acid by sPLA2GIIA. sPLA2GIIA can degrade membrane bound 
phosphatidylcholine to release arachidonic acid. Arachidonic acid can then be used in the Cox 1/2 and Lipoxygenase 
pathways to produce inflammatory eicosanoids such as prostaglandins, leukotrienes, thromboxanes, etc. Current inhibitors 
of this pathway include Aspirin, NSAIDs, and corticosteroids. 
 
former of which can then be used in the formation of inflammatory signaling molecules 
called eicosanoids which are known to play a role in inducing inflammation, pain, fever, and 
modulating aspects of the immune system (3, 4). It is also understood that these enzymes 
have been correlated with the severity of multiple inflammatory diseases such as 
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cardiovascular disease (5), rheumatoid arthritis (6, 7), and cancer (8, 9). In many of these 
diseases, overexpression of sPLA2s have been positively correlated with disease progression 
or severity. For example, elevated levels of sPLA2GIIA in the blood has been used as a 
reliant biomarker for atherosclerosis for over a decade (10, 11). Although these correlations 
can be helpful when determining the presence of a disease it is still not known whether or not 
treating these high sPLA2 levels will effectively treat these diseases in humans. However, 
studies have shown that by decreasing or knocking out the expression of various sPLA2s, 
treatment and/or prevention of some inflammatory diseases are possible in mice.  
 In 2010 researchers found that transgenic mice that overexpress the sPLA2GIIA 
enzyme have a significantly increased susceptibility to K/BxN autoantibody induced arthritis. 
They also found that sPLA2GIIA knockout mice were protected from the same induced 
arthritis model compared to wild-type mice (6). Another study showed that transgenic mice 
that overexpress sPLA2GIIF were more sensitive to a 7, 12-Dimethylbenantheracene 
(DMBA) chemical carcinogenesis model and developed larger skin tumors than wild-type 
mice. sPLA2GIIF knockout mice, again, were found to be significantly more resistant and 
developed fewer skin tumors (12, 13). These studies give evidence that inflammatory 
diseases that overexpress sPLA2s could potentially be treated by genetic regulation or 
specific and effective sPLA2 inhibitors. 
While there are various other examples of sPLA2 knockout mice showing protection 
or resistance to inflammatory disease models, there are also studies that show overexpression 
of sPLA2s can be beneficial to some diseases. Gastric cancer patients whose tumors express 
high levels of sPLA2GIIA have been found to have a significantly improved rate of survival 
and decreased metastasis versus those patients whose tumors express low levels of 
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sPLA2GIIA (14). sPLA2GV knockout mice show exacerbated symptoms in a mouse model 
with induced arthritis, and more interestingly, these symptoms can be somewhat rescued via 
the introduction of exogenous sPLA2GV (15). While the evidence for the therapeutic 
potential of sPLA2 inhibitors is probable the contravening roles of various sPLA2s even 
within the same disease, such as sPLA2GIIA and V in arthritis, make it troublesome to 
implement. This is mainly due to a lack of specific and effective inhibitors.  
There have been many effective sPLA2 inhibitors over the years. Many have made it 
to clinical trials, but none have made it to market. This is mainly due to non-specific 
inhibition. YM-26734 and KH064 are two effective inhibitors of sPLA2s that have been 
shown to decrease inflammation in rat ear edema (16), protect against intestinal reperfusion 
injury (17), attenuate NF-kB activity in lung cancer cells (18), and protect against diet-
induced metabolic syndrome in rats (19). However, these inhibitors target many sPLA2s and 
can thus have multiple side effects (20, 21). As a result, these drugs have mostly been 
relegated to the lab rather than going on to become treatments. Varespladib, a sPLA2GIIA 
inhibitor, failed to reduce rheumatoid arthritis in a double blind study during clinical trials 
(22). This has been attributed to non-specific inhibition of sPLA2GV, which has been shown 
to reduce arthritis in arthritic-induced mouse models (15). In another clinical trial for 
cardiovascular disease Varespladib showed a 90% reduction in sPLA2GIIA activity and was 
effective in reducing LDL cholesterol, but later showed increased incidence of myocardial 
infarction and total cardiovascular events during phase 3 trials. Again this has been attributed 
to non-specific inhibition of sPLA2GV and/or group X since Varespladib inhibits these 
enzymes at similar concentrations (23, 24). These studies show that sPLA2 inhibitors do have 
therapeutic potential for some inflammatory diseases, but the creation of specific inhibitors is 
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at this point lacking. The mechanism by which most sPLA2 inhibitors function, Varespladib 
included, is through competitive inhibition. Researchers use amphipathic molecules that 
integrate into the membrane and when brought into the catalytic site are not able to be 
hydrolyzed by the enzyme. This effectively extends the time between enzyme substrate 
interactions and decreases the overall reaction rate (Figure 2). The more time the inhibitor 
spends in the catalytic site, the lower the dissociation constant (KD), the more effective the 
inhibitor. Thus, the lack of specific inhibitors is mainly due to how similar in structure and 
function sPLA2s are to one another. 
 
Figure 2. Competitive inhibition of an sPLA2. Once the competitive inhibitor (blue) is integrated into the 
membrane (pink) the sPLA2 will bring the non-hydrolysable inhibitor into the active cite (green) for a period of 
time preventing the binding of substrate (purple). Eventually, the enzyme will release the inhibitor back into the 
membrane and continue its function. 
  
sPLA2GV and IIA have high homology (~40%) with the difference coming from 
group V lacking one of the disulfide bonds found within group IIA. Although these groups 
are very similar the difference in one disulfide bond gives each enzyme varying affinities 
towards their substrates. Group V is able to hydrolyze phosphatidylcholine more effectively 
than group IIA, which conversely has a higher affinity towards phosphatidylethanolamine 
(25). Isoforms IIA, IIC, IID, IIE, and IIF only differ by C-terminal extensions of varying 
length and composition (26). While these differences are notable the active site within these 
enzymes containing the His-Asp catalytic dyad are almost identical. This homology, 
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particularly in the active site, is what makes finding specific inhibitors of each enzyme 
remarkably difficult.  
 PLA2s in general are interfacial enzymes because they have to interact with a 2D 
amphipathic structure such as a membrane, vesicle, or micelle in order to reach their 
substrate. Interfacial enzyme kinetics tend to be more complicated than matrix enzymes due 
to this interaction. Matrix enzymes are able to find their substrates in solution, and therefore, 
the standard reaction rates are easily determined because each enzyme is exposed to the same 
environment. Each interfacial enzyme, however, is not exposed to the same environment 
since substrate concentration, non-substrate concentration, membrane type, and membrane 
size from one interface to another can vary greatly. As these factors change so does the 
enzymatic rate of reaction. This issue has led to the development of kinetic models. The 
surface dilution model estimates the effect of heterogeneously mixed interfaces on enzymatic 
rates of reaction (27, 28). For example, researchers looked at the differences in reaction rate 
of the cobra venom sPLA2 when it was introduced to various concentrations of Triton X-100 
and phosphatidylcholine in mixed micelles (27, 29). These studies found that as the ratio of 
Triton X-100 to substrate increased, the reaction rate of cobra sPLA2 severely decreased even 
though there was no direct change in overall substrate concentration (Figure 3). This decrease 
in enzyme activity was due to a decrease in the number of enzyme/substrate interactions 
overall. This surface dilution effect can represent either a decrease in substrate concentration 
or an increase in non-hydrolysable molecules within a micelle. Thus, inhibition studies must 
be performed without surface dilution having an effect on enzymatic reaction rates as to not 
give a false positive.  
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Figure 3. Surface Dilution Example. From left to right is an example of surface dilution occurring on the same area of a 
micelle (black box) when sPLA2 substrate (red circle) is diluted with Triton X-100 (blue triangle). 
 
sPLA2 reaction rates can also be slowed, or show a false positive, by a change in 
micelle structure. Fortunately, nonionic detergents do not distort micelle structure when 
above their critical micelle concentration. This means that with the use of nonionic 
detergents, like Triton X-100, the addition of lipids at small mole fractions would not have a 
significant effect on micelle structure and thus should not affect reaction rates. Another 
benefit of nonionic detergents is that as lipids are added they become uniformly solubilized 
into a homogeneous micelle mixture (30). This homogeneity allows for even distribution of 
lipids so that variation between micelles is low and inhibitor studies can be performed 
without surface dilution or micelle distortion leading to skewed results.  
 Specific, effective, and natural inhibitors of sPLA2s are needed in order to further our 
understanding of these enzymes as well as to determine if their inhibition within 
inflammatory diseases could yield effective treatments. During the initial phase of this study, 
in which a potential new inhibitor was being tested, an unknown inhibition phenomenon was 
found. When natural lipid extracts were added to a sPLA2 assay in concentrations that cannot 
cause surface dilution, substantial inhibition was observed. The subsequent study set out to 
characterize the chemical structural elements that may be responsible for this inhibition.  
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Materials and Methods 
2.1 sPLA2 Assay Stock Reagents 
 All chemicals are from Millipore Sigma unless otherwise stated. Assay buffer stock 
(25 mM Tris-HCl, 10mM CaCl2, 100 mM KCl, 0.3 mM Triton X-100, pH 7.5) and Tris-HCl 
stock (0.4 M Tris-HCl, pH 8.0) was stored at 4˚C. Aliquots of Crotalus adamanteus (eastern 
diamondback rattlesnake) sPLA2GIIA (0.025mg/mL) were stored at -20˚C. 1,2-
dithioheptanoyl-sn-glycero-3-phosphorylcholine (diheptanoyl-thio-PC) (10 mM) and 1-
palmitoyl-2-thio-arachidonoyl-sn-glycero-3-phosphorylcholine (arachidonoyl-thio-PC) (10 
mM) in 9:1 chloroform: methanol were stored at -20˚C. Bovine serum albumin (BSA) in 
assay buffer solution (1mg/mL) along with Ellman’s reagent (5-5’-dithio-bis-(2-nitrobenzoic 
acid)/DTNB (30mM)) were prepared weekly and stored at 4˚C between assays. Before 
assays an aliquot of either diheptanoyl-thio-PC or arachidonoyl-thio-PC substrate was 
evaporated under a stream of nitrogen and re-suspended/water bath sonicated with BSA and 
assay buffer solution to a final concentration of 5 mM. Lipid additives (dioctanoyl-PC, egg-
PC, oleic acid, heptanoic acid, deoxycholic acid, tween 20, or hexylamine) were evaporated 
under a stream of nitrogen and re-suspended in DMSO: ethanol (EtOH) (1:1) by vortexing 
and water bath sonication. Dilution to achieve needed total mole fractions were made in the 
assay buffer described above. Total mole fraction = [additive]/ [additive + substrate + 
detergent].  
2.2 Diheptanoyl-Thio-PC sPLA2 Assay  
 This assay was based on the sPLA2 assay protocol from Reynolds, Hughes, and 
Dennis (31). This sPLA2 assay was performed in 96 microwell plates. Each well contained 
85 µL of BSA (1mg/mL), 10 µL of 30 mM Ellman’s reagent (DTNB), 50 µL of 5 mM 
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diheptanoyl-thio-PC substrate, and 5 µL of either lipid additive or vehicle control (1:1 
DMSO: EtOH). Negative control wells received 90 µL BSA (1mg/mL). A final volume in 
each well of 155 µL was reached after enzyme addition (5 µL). Next, the plate was placed on 
a plate shaker for 5-10 minutes. After mixing, positive control and experimental groups were 
challenged with 5 µL of 0.025mg/mL Crotalus adamanteus sPLA2GIIA mixed by pipetting 
then immediately placed on Molecular Devices M2 plate reader set to 414 nm at room 
temperature (~23˚C). Plates were read every 30 sec for 8 minutes. Each experimental assay 
was replicated in triplicate.  
 Crotalus adamanteus sPLA2GIIA enzyme, when added, will hydrolyze the sn-2 
glycerol position of the thio-labeled substrate (diheptanoyl-thio-PC or arachidonoyl-thio-PC). 
In turn the sulfide on the lysophospholipid will react with Ellman’s reagent to produce a 5-
thio-2-nitrobenzoic acid. The production of 5-thio-2-nitrobenzoic acid leads to a measurable 
colorimetric change.  
 
2.3 Arachidonoyl-Thio-PC cPLA2 Assay 
 This procedure was based on a cPLA2 assay kit procedure from Cayman Chemical 
(Item #765021). This assay was performed exactly as the diheptanoyl-thio-PC assay 
described above except the assay buffer stock was prepped with 8.0 mM Triton X-100, 2-
deoxy-2-thio arachidonoyl PC was used as the substrate, and the temperature of the 
spectrophotometer was set at 37˚C, unless otherwise stated. 
Statistical Analysis 
 Percent activity values were determined by comparing the slope of the experimental 
groups with the slope of the control group. The statistical analysis of this data was performed 
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in Microsoft Excel. An analysis of variance (F-test) was used to determine if two sets of data 
at the same mole fraction/concentration contained equal variances. A Student T-test was used 
to signify the differences in percent activity between two experimental groups at a 
significance level of p < 0.05.  
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Results and Discussion 
3.1 PLA2 Assay Functionality 
 The diheptanoyl-thio-PC (sPLA2) assay was tested with a known inhibitor, YM-
26734, to determine if the assay was functioning similar to Myake, A. et al. (16). YM-26734 
has an average IC50 of 0.085 µM with a range from 0.056-0.129 µM against rabbit 
sPLA2GIIA. Crotalus adamanteus sPLA2GIIA should act similar to rabbit sPLA2GIIA since 
both mammals and snakes have similar sPLA2 crystal structures (32). Since the standard 
diheptanoyl-thio-PC assay required a higher enzyme concentration a proportionate amount of 
YM-26734 was used, thus the inhibitor concentrations 0.125, 0.935, and 1.75 µM were tested 
(Figure 4). An IC50 of 0.67 µM was calculated. Since this was near published values it was 
concluded that the assay and response to lipidic inhibitors was functioning similarly to the 
rabbit enzyme in other labs (16). 
 
Figure 4. Inhibition of sPLA2 by YM-26734. Percent activity curve for known inhibitor YM-26734 (blue). 
YM-26734 inhibited sPLA2GIIA from Crotalus adamantus with an IC50 of ~0.67 µM. Values represented as 
averages + standard deviation and n = 3. 
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3.2 Effect of Dioctanoyl-PC and Egg-PC on PLA2 Activity in Diheptanoyl-Thio-PC Assay 
 Dioctanoyl-PC (DC8PC) was added to the sPLA2 assay in small molar fractions as a 
potential control for future natural lipidic inhibitors. DC8PC was added as stated in section 2.2 
with mole fraction relative to total lipid present (total mole fraction). At a mole fraction of 
1.7x10-2 DC8PC decreased enzymatic activity by 85% compared to control (Figure 5). At mole 
fractions of 1.7x10-4, 1.7x10-6, 1.7x10-8, and 1.7x10-10 DC8PC had less of an effect on 
sPLA2GIIA with a decrease in activity of around 65%. The “inhibitory effect” of DC8PC 
should not have been as drastic as was observed according to the surface dilution model (28). 
At these low mole fractions there was more of an effect than would be predicted if surface 
dilution or affinity was the main contributor. Indeed, when adding DC8PC at one molecule in 
1010 there was a 65% inhibition. At this concentration there should be undetectable surface 
dilution or occupation of the enzyme by unlabeled substrate. The “inhibitory effect” did 
subside after a mole fraction of 1.7x10-15 was achieved (98.1 + 2.99% of control).  
 In order to determine if the same “inhibitory effect” would be seen with longer and 
unsaturated fatty acid chains, egg-phosphatidylcholine (egg-PC, 18 carbon) was added in the 
same mole fractions as DC8PC (8 carbon) in hopes that the resulting increase in fluidity would 
allow the enzyme to run at 100% activity. At 1.7x10-2 mole fraction egg-PC yielded the same 
result as DC8PC at the same mole fraction (Figure 5). As the concentration increased, the 
sPLA2GIIA activity decreased, similar to DC8PC. Moreover, with egg-PC, the activity still did 
not reach expected levels of 100% activity.  
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Figure 5. DC8PC and egg-PC’s effect on Crotalus adamanteus sPLA2GIIA. Molar fractions of dioctanoyl-
PC (blue) and egg-PC (orange) were added to the assay to determine their effect on sPLA2GIIA percentage of 
activity. Values represented as average + standard deviation (error bars) and n = 3. 
 
3.3 Effect of Dioctanoyl-PC and Egg-PC on PLA2 Activity in Arachidonoyl-Thio-PC Assay 
 Next, we wanted to see if the same inhibition would occur with a long chain 
substrate. The three higher concentrations of DC8PC and egg-PC from the diheptanoyl-thio-
PC assay (see 3.2) were tested again here using long-chain (2-deoxy-2-thio arachidonoyl PC) 
as the labeled substrate with the same enzyme, Crotalus sPLA2GIIA as above. The assay 
with this substrate requires changes in Triton X-100 concentration (8.0 mM) and temperature 
(37˚C). These conditions were tested to determine if the “inhibitory effect” seen previously 
(Section 3.2) was due to an unfavorable enzyme environment. Had the inhibition been due to 
the substrate’s short fatty acids (8 carbons), then the arachidonoyl-thio-PC assay (20 carbons) 
should not show any inhibition. Total mole fraction changes in relation to the concentration 
of detergent in the assay (see equation in section 2.1). Since the diheptanoyl-thio-PC and 
arachidonoyl-thio-PC assays differ in Triton X-100 concentration the total mole fraction 
would be different and a direct comparison could not be made, thus it was decided to keep 
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the concentration/number of DC8PC and egg-PC added to the assays the same across 
subsequent tests; thus the concentration of lipid introduced was used as an x-axis for 
comparison purposes. 
DC8PC caused significantly less reduction of activity in the arachidonoyl-thio-PC 
assay than in the diheptanoyl-thio-PC assay (Figure 6). sPLA2 activity was 24-28% higher in 
the arachidonoyl-thio-PC assay (dashed vs solid) at all three tested concentrations (p = 
7.5x10-4, 1.3x10-5, and 5.4x10-5). However, activity still failed to reach expected values of 
100% activity at any mole fraction.  
The difference in inhibition by egg-PC between diheptanoyl-thio-PC and 
arachidonoyl-thio-PC was statistically significant at the lowest (5x10-4 nmol) and highest (5 
nmol) concentrations of lipid introduced (p = 0.027 and 5.4x10-6, respectively), but not at the 
intermediate concentration (5x10-2 nmols) (p = 0.055) (Figure 7). Overall, the “inhibitory 
effect” was still present with the addition of either lipid in both assay conditions although the 
arachidonoyl-thio-PC did show less of a reduction. A change in assay conditions inherent 
between the two assays may lead to expected values of 100% activity.  
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Figure 6. DC8PC in diheptanoyl-thio-PC and arachidonoyl-thio-PC assay conditions. Differences in 
percent activity for DC8PC (blue) in diheptanoyl-thio-PC (solid) and arachidonoyl-thio-PC (dashed) assays. 
Higher values indicate less inhibition of the enzyme. Values represented as averages + standard deviation and n 
= 3.  
 
 
 
Figure 7. Egg-PC in diheptanoyl-thio-PC and arachidonoyl-thio-PC assay conditions. Differences in 
percent activity for egg-PC (orange) in diheptanoyl-thio-PC (solid) and arachidonoyl-thio-PC (dashed) assays. 
Higher values indicate less inhibition of the enzyme. Values represented as averages + standard deviation and n 
= 3.  
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3.4 Effect of Arachidonoyl-Thio-PC Assay conditions on PLA2 Activity 
 The differences in effect between of DC8PC and egg-PC in the arachidonoyl-thio-PC 
and diheptanoyl-thio-PC assays, described in section 3.3, could have been due to changes in 
Triton X-100 concentration, temperature, or the substrate itself. The effects of each variation 
in conditions between the arachidonoyl-thio-PC and diheptanoyl-thio-PC assays were 
separately examined while keeping the concentrations of added DC8PC and egg-PC constant.  
 Triton X-100 concentration was the first variable examined. In the diheptanoyl-thio-
PC assay Triton X-100 was 0.3 mM, however, this was increased to 8.0 mM for the 
arachidonoyl-thio-PC assay (see Figure 6 and Sections 2.1 and 2.3), thus the same 
diheptanoyl-thio-PC assay (challenged with DC8PC) was performed except a concentration 
of 8.0 mM Triton X-100 was used. This increase in detergent increased sPLA2 activity in the 
diheptanoyl-thio-PC assay by approximately 15% at each concentration (Figure 8). This 
increase in detergent should have reduced percent activity according to the surface dilution 
model as the substrate molecules become more spread out in the membrane (29). However, 
here it is shown that an increase in detergent alone significantly increased activity. This 
increase in activity may be explained by the “surface binding model” in which the increase in 
detergent leads to the formation of more micelle surface area (33). Since there was an 
increase in micelle number more enzymes were able to bind more effectively and therefore 
the inhibitory effect of dioctanoyl-PC on the assay was lessened resulting in an increase in 
overall percentage of activity.  
 The second variable to be examined was temperature. While the diheptanoyl-thio-PC 
assay was performed at room temperature (23˚C) the arachidonoyl-thio-PC assay was 
performed at human body temperature (37˚C). As shown in Figure 8, temperature does have 
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a significant effect at all three concentrations tested. Phospholipases A2 along with other 
enzymes function more effectively at warmer temperatures, and thus a rise in percent activity 
was expected. Another factor is an expected increase in micelle membrane fluidity and lateral 
lipid diffusion. The overall increase in activity seen in Figure 8 is likely a combination of the 
two effects. However, since degradation of enzyme would occur at higher assay temperatures 
increasing the temperature of the assay would not be a viable option for reaching 100% 
activity.  
 Finally, the effect of substrate fatty chain can be seen when comparing the standard 
arachidonoyl-thio-PC assay to the temperature and detergent varied diheptanoyl-thio-PC 
assay. Although the percentage of activity between the two are similar there is a significant 
difference between arachidonoyl and diheptanoyl substrates at concentrations 5.0x10-4 and 
5.0x10-2 (p = 0.045 and 6.9x10-3, respectively) (Figure 8). This difference is due to the 
difference in fatty acid length. The heptanoylacyl groups are saturated and short (7 carbons) 
while arachidonoyl groups are polyunsaturated and long (20 carbons). Although both of these 
molecules are good substrates for the sPLA2GIIA used, this difference might be due to a 
slight difference in substrate affinity or due to the difference in fatty acid length (31, 34). 
With the condition effects established we examined the effect of various structural 
elements of substrate analogs. As observed with the diheptanoyl-thio-PC assay, the 
arachidonoyl-thio-PC showed a large decrease in activity with the addition of DC8PC even at 
these low concentrations. Since there was a difference of activity between the two substrates 
alone, regardless of assay conditions, fatty acid length may be affecting micelle structure in 
some way to cause this decrease in activity seen in all tests thus far.  
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Figure 8. Effects of Assay Conditions on PLA2 Activity. DC8PC in diheptanoyl-thio-PC (solid blue) and 
arachidonoyl-thio-PC (dashed blue) assays were carried over from figure 6 as a reference. DC8PC in 
diheptanoyl-thio-PC assay with a rise in Triton X-100 concentration from 0.3 mM to 8.0 mM (green). DC8PC in 
diheptanoyl-thio-PC assay with an increase in Triton X-100 concentration (8.0 mM) and temperature (from 
23˚C to 37˚C) (red). DC8PC in arachidonoyl-thio-PC assay with an increase in Triton X-100 concentration (8.0 
mM), temperature (37˚C), with arachidonoyl-thio-PC substrate (dashed blue). Values represented as averages + 
standard deviation and n = 3. 
 
3.5 Effects of Fatty Acid Length on PLA2 Activity 
 In Section 3.4, the increase in fatty acid length and unsaturation of arachidonoyl-thio-
PC vs diheptanoyl-thio-PC, was shown to have lessened the “inhibitory effect” of DC8PC on 
the assay. We set out to determine if the fatty chains themselves were causing this 
phenomenon. We used oleic acid (18 carbons) and heptanoic acid (7 carbons). Fatty acids 
have the added benefit of not being a potential substrate for the enzyme unlike DC8PC or 
egg-PC. This prevents any decrease in activity to be attributed as enzyme affinity towards an 
unlabeled substrate. In order to directly maintain the fatty acids at the same concentration as 
DC8PC and egg-PC the concentrations of fatty acids were two times the PC concentrations, 
i.e. two fatty acids would substitute for one phospholipid.  
 At 1.7x10-2 and 1.7x10-4 mole fraction both heptanoic acid and oleic acid had similar 
inhibitory effects on sPLA2 activity (Figure 9). At 1.7x10
-6 mole fraction however heptanoic 
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acid continued to follow the same trend as egg-PC, but oleic acid decreased in percent 
activity and was significantly different from heptanoic acid (p = 1.9x10-2). Overall, we can 
infer that fatty acid length is not the critical factor responsible for the inhibitory phenomenon. 
These results also tell us that the difference seen in Figure 8 between the two substrates may 
be due to affinity for the enzyme and not due to fatty acid length. Oleic and heptanoic acids 
showed the same activity trend as egg-PC i.e. all three showed ~40% reduction in activity 
(Reference Figure 5). Therefore, with this data it can be concluded that fatty acid length and 
presence of a phosphorylcholine group are not the major contributing factors to this 
“inhibitory effect.”  
 
 
Figure 9. Effects of Fatty Acid Length on PLA2 Activity. Oleic acid (yellow) and heptanoic acid (light blue) 
were tested in the diheptanoyl-thio-PC assay. Values represented as averages + standard deviations with n = 3.  
 
3.6 Effects of Ionic and non-Ionic Detergents on PLA2 Activity 
 Next, we wanted to determine if the charge of the lipid additives is a key factor in 
sPLA2 inhibition. The ionic detergent deoxycholic acid and the non-ionic detergent tween 20 
were chosen to represent a negative and positively charged additive, respectively. The non-
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ionic detergent, Triton X-100, was used in the standard diheptanoyl-thio-PC assay. In Figure 
8, where the Triton X-100 concentration was increased from 0.3 mM to 8.0 mM there was no 
variation to the control (mole fraction of 0), thus Triton X-100 was inadvertently shown to 
not have an inhibitory effect when added to the assay. 
 Deoxycholic acid followed a similar “inhibitory” pattern to that of egg-PC in which 
both deoxycholic acid (Figure 10), heptanoic acid, and oleic acid (Figure 9) had similar 
percent activities at each mole fraction. Tween 20, interestingly, did not inhibit the reaction 
but slightly increased the reaction rate at the highest mole fraction (1.7x10-2), although not 
significantly (Figure 10). This result departed from all of the amphipathic molecules tested 
thus far. This may be due to its lack of charge. Deoxycholic acid, oleic acid, heptanoic acid, 
dioctanoyl-PC, and egg-PC all have partial or full ionic charges, and more specifically 
exhibit negative charges (at pH = 7.0-7.4). Presumably, the addition of these charges affect 
the overall surface charge which can significantly impact the physical interaction of an 
enzyme with its interface. sPLA2s utilize hydrophobic and hydrophilic amino acids in order 
to incorporate themselves into a lipid interface as well as interact with an interface’s surface. 
If an interface’s surface charge changes significantly enough, then the amino acids associated 
with the interface may not be able to interact as effectively (33). If the surface charge is 
preventing the binding of sPLA2GIIA here, then we would expect to see a decrease in 
reaction rate or “inhibitory effect”. This seems to be what we have seen thus far. However, if 
a lipid was incorporated and did not interfere with surface charge, then we would not expect 
to see a decrease in reaction rate. In Figure 10 we see that tween 20, which is non-ionic, does 
not reduce reaction rate. This lack of “inhibitory effect” is attributed to a lack of change in 
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overall surface charge. However, historically sPLA2s have been shown to prefer binding to 
anionic surfaces, thus a binding study would likely clarify this phenomenon (35).   
 
 
Figure 10. Effects of Fatty Chain Charge on sPLA2 Activity. Effects of deoxycholic acid (red) and tween 20 
(green) on diheptanoyl-thio-PC assay. Values represented as averages + standard deviation and n = 3. 
 
 In order to further support that charge as the basis for the “inhibitory effect” we tested 
the fatty amine, hexylamine, containing six carbons and a cationic primary amine. 
Hexylamine, at low mole fractions, showed no significant effect on sPLA2 activity, similar to 
results with tween 20 (Figure 11 and 10, respectively). At the higher mole fractions of 8x10-2 
and 3x10-1 (50% and 90% of [substrate]), hexylamine had percent activities at 45.8 + 2.67% 
and 18.4 + 0.90% respectively, consistent with that of surface dilution (Figure 11). Therefore, 
when non-ionic or positively charged lipids are incorporated at low mole fraction a reduction 
in reaction rate is not seen. This evidence supports the conclusion that the negative charge is 
responsible for the decrease in reaction rate of sPLA2.  
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Figure 11. Effects of Hexylamine on sPLA2 Activity. Effects of hexylamine (purple) on diheptanoyl-thio-PC 
assay.  Values represented as averages + standard deviation and n = 3. 
 
3.7 Future Directions 
 Since the results seen here do not match up with the expected results according to 
various models established in the literature future research should be focused on the 
characterization of this phenomenon. One potential future direction is the testing of other 
lipid additives in this assay to expand on the tests performed here. Such tests could include 
adding lipids that are more positively or negatively charged to the assay and determining 
their effect on the rate of reaction. Another such test could determine if the molecular size of 
the lipid additive would have an effect on the rate of reaction. These tests would not only 
confirm the presence of this phenomenon, but would also expand the understanding behind 
the mechanism by which it is acting.  
 A second future direction would be the testing of this phenomenon in other sPLA2 
assays such as the EnzChekTM (Product #E10217) assay which utilizes a fluorescent 
detection method. Since that technique is substantially different if the inhibition phenomenon 
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were to still be present then it would suggest that the effect is more generally applicable. 
Conversely, if the inhibition phenomenon seen here did not occur in the EnzChekTM assay 
with the same lipid additives, then this phenomenon could be due to the specifics of the 
thiolipid assay. 
 The structure of the micelles themselves could be imaged under scanning or transition 
electron microscopy before and after the addition of these additives in order to determine if 
the overall structure of the micelle changes. Along with these techniques a radioactive 
labeled lipid could be added to a micelle and imaged to determine if and how the lipid 
becomes incorporated within the existing micelle. This test would also be beneficial by 
showing whether or not the lipid additives are aggregating on the surface of the micelle. If 
this were to occur then an sPLA2 enzyme may become lodged in this “lipid aggregate” which 
would affect enzyme activity.  
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Conclusion 
 In this study, a large “inhibitory effect” on PLA2 activity was seen when lipids were 
added at molar fractions below what surface dilution models can explain. This was seen with 
phospholipids, fatty acids, and detergents. Evidence points to this being due to a change in 
micelle surface charge, more specifically a negative charge. Past literature suggests that 
phospholipases A2 typically have a higher affinity for anionic lipid interfaces, and the 
addition of lipids at these mole fractions should not affect the physical characteristics of a 
micelle such as size, charge, or area per molecule (32, 34). However, this study suggests that 
these subjects be revisited and further investigated. Thus, it is important to recognize these 
type of effects when performing future inhibition studies on interfacial enzymes such as 
sPLA2s. 
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